Prevalence of transmission of zidovudine-resistant viruses in Switzerland;Prevalence de la transmission de virus resistant a la zidovudine en Suisse

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 43, 1996, Pages 1845-1848

  Yerly, S ^a   Rakik, A ^a   Kinloch de Loes, S ^a   Erb, P ^b,d   Vernazza, P ^c,g   Hirschel, B ^a,g   Perrin, L ^a,h,i   Battegay, M ^d   Burgisser Ph ^d   Doorly, R ^d   Egger, M ^d   Fierz, W ^e   Flepp, M ^e   Francioli, P ^f   Grob, P ^g   Gruninger U ^g   Ledergerber, B ^h   Luthy R ^h   Malinverni, R ^h   Matter, L ^h   Opravil, M ^h   Paccaud, F ^h   Pichler, W ^h   Rickenbach, M ^h   Rutschmann, O ^g   Von Overbeck, J ^g   more..

^a Hôpital Universitaire   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d Groupe Laboratoires   (France)

^e Groupe Clinique

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g FOPH ^*

^h Centre de Base de Donnée   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE; ANTIVIRUS AGENT; VIRUS DNA;

CONFERENCE PAPER; DRUG RESISTANCE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; SWITZERLAND; VIRUS ISOLATION; VIRUS MUTANT; VIRUS TRANSMISSION; ADOLESCENT; ADULT; ARTICLE; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA, VIRAL; DRUG RESISTANCE; FEMALE; HIV; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; ZIDOVUDINE;

EID: 0030603259     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. McLeod GX, Hammer SM: Zidovudine: five years later. Ann Intern Med 1992; 117: 487-501.
2. Fischl MA, Richman DD, Grieco MH et al.: The efficacy of azidothymine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med 1987; 317: 185-191.
3. Fischl MA, Richman DD, Causey DM et al.: Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989; 262: 2405-2410.
4. Concorde Coordinating Committee. Concorde: MRC/ARNS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
5. Larder BA, Darby G, Richman DD: HIV-1 with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-1734.
6. Richman DD, Grimes JM, Lagakos SW: Effect of stage disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990; 3: 743-746.
7. Kellam P, Boucher CA, Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89: 1934-1938.
8. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level of resistance to zidovudine (AZT). Science 1989; 246: 1155-1157.
9. Boucher CA, O'Sullivan E, Mulder JW et al.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105-110.
10. Erice A, Mayers DL, Strike DG et al.: Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Eng J Med 1993; 328: 1163-1165.
11. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
12. Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin L: Early and prolonged decrease of viremia in HIV-1 infected patients treated with didanosine. J Acquir Immune Defic Syndr 1995; 8: 358-364.
13. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991; 5: 137-144.
14. Mayers DL, Yerly S, Perrin L et al.: Prevalence of AZT-resistant HIV-1 in persons seroconverting in Switzerland, Australia and the United States between 1988 and 1994. Abstract. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 1994.
15. De Ronde A, Shuurman R, Goudsmit J, Van den Hoek A, Boucher CA: First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. AIDS 1996; 10: 231-232.
16. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993; 167: 526-532.
17. Rouzioux C: Prevention of maternal HIV transmission. Practical guidelines. Drugs 1995; 49 (Suppl 1): 17-24.
18. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L: Mother to child transmission of zidovudine-resistant HIV-1. Lancet 1994; 344: 1771-1772.
19. Mellors JW, Larder BA, Schinazi RF: Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. MediTech Media Ldt: International Antiviral News, 1995.
20. Shafer RW, Kosal MJ, Winters MA et al.: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique pattern of pol gene mutations. J Infect Dis 1994; 169: 722-729.
21. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-699.